Albumin and multiple sclerosis: a prospective study from UK Biobank

BackgroundMultiple sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system. While previous studies have indicated that albumin, the primary protein in human plasma, may exert influence on the inflammatory process and confer beneficial effects in neurodegenerative disorders, its role in the context of MS has been underexplored. Here, we aimed to explore the link between albumin and the risk of MS.MethodsEmploying data from the UK Biobank, we investigated the association between baseline levels of serum and urine albumin and the risk of MS using Cox proportional hazards regression analysis.ResultsA higher baseline level of serum albumin was associated with a lower risk of incident MS (HR=0.94, 95% CI: 0.91–0.98, P=7.66E-04). Subgroup analysis revealed a more pronounced effect in females, as well as participants with younger ages, less smoking and deficient levels of vitamin D. Conversely, no association was identified between baseline microalbuminuria level and risk of incident MS.ConclusionHigher serum albumin level at baseline is linked to a reduced risk of MS. These results contribute to an enhanced understanding of albumin’s role in MS, propose the potential use of albumin as a biomarker for MS, and have implications for the design of therapeutic interventions targeting albumin in clinical trials.